This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Yale University Identifier:
First received: October 7, 2005
Last updated: June 5, 2014
Last verified: June 2014
This study will compare the effectiveness of newer atypical antipsychotics versus older conventional antipsychotics in treating schizophrenia.

Condition Intervention Phase
Schizophrenia Drug: risperidone Drug: olanzapine Drug: quetiapine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Effectiveness of Atypical Vs Conventional Antipsychotics

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Retention.

Secondary Outcome Measures:
  • EPS, TD.

Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)
Detailed Description:
At seven participating hospitals, acutely exacerbated patients with schizophrenia were randomly assigned to treatment with antipsychotic from the atypical class vs antipsychotic from the conventional class. Medication choice within class, dose, concomitant medications, and other prescribing decisions were left to the community prescriber. Patients were followed for one year after discharge.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hospitalized for schizophrenia

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00237861

Sponsors and Collaborators
Yale University
National Institute of Mental Health (NIMH)
Principal Investigator: Scott W Woods, MD Yale University
  More Information

Responsible Party: Yale University Identifier: NCT00237861     History of Changes
Other Study ID Numbers: MH57292
R01MH057292 ( U.S. NIH Grant/Contract )
Study First Received: October 7, 2005
Last Updated: June 5, 2014

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Quetiapine Fumarate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators processed this record on August 18, 2017